425 related articles for article (PubMed ID: 32896549)
1. The cannabinoid CB
Iyer V; Slivicki RA; Thomaz AC; Crystal JD; Mackie K; Hohmann AG
Eur J Pharmacol; 2020 Nov; 886():173544. PubMed ID: 32896549
[TBL] [Abstract][Full Text] [Related]
2. Slowly Signaling G Protein-Biased CB
Lin X; Dhopeshwarkar AS; Huibregtse M; Mackie K; Hohmann AG
Mol Pharmacol; 2018 Feb; 93(2):49-62. PubMed ID: 29192123
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid CB
Zavala CA; Thomaz AC; Iyer V; Mackie K; Hohmann AG
Cannabis Cannabinoid Res; 2021 Oct; 6(5):389-400. PubMed ID: 33998863
[No Abstract] [Full Text] [Related]
4. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
5. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.
Li AL; Lin X; Dhopeshwarkar AS; Thomaz AC; Carey LM; Liu Y; Nikas SP; Makriyannis A; Mackie K; Hohmann AG
Mol Pharmacol; 2019 Feb; 95(2):155-168. PubMed ID: 30504240
[TBL] [Abstract][Full Text] [Related]
7. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.
Grenald SA; Young MA; Wang Y; Ossipov MH; Ibrahim MM; Largent-Milnes TM; Vanderah TW
Neuropharmacology; 2017 Apr; 116():59-70. PubMed ID: 28007501
[TBL] [Abstract][Full Text] [Related]
8. Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain.
Guenther KG; Xu Z; Romero J; Hillard CJ; Mackie K; Hohmann AG
Neuropharmacology; 2023 Oct; 237():109601. PubMed ID: 37286073
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid CB
Guenther KG; Lin X; Xu Z; Makriyannis A; Romero J; Hillard CJ; Mackie K; Hohmann AG
bioRxiv; 2024 Mar; ():. PubMed ID: 38496640
[TBL] [Abstract][Full Text] [Related]
10. Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of anti-retroviral toxic neuropathy.
Carey LM; Xu Z; Rajic G; Makriyannis A; Romero J; Hillard C; Mackie K; Hohmann AG
Pharmacol Res; 2023 Jan; 187():106560. PubMed ID: 36417942
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid CB
Guenther KG; Lin X; Xu Z; Makriyannis A; Romero J; Hillard CJ; Mackie K; Hohmann AG
Biomed Pharmacother; 2024 Jun; 176():116879. PubMed ID: 38850666
[TBL] [Abstract][Full Text] [Related]
12. Positive Allosteric Modulation of CB
Slivicki RA; Iyer V; Mali SS; Garai S; Thakur GA; Crystal JD; Hohmann AG
Front Mol Neurosci; 2020; 13():54. PubMed ID: 32410959
[TBL] [Abstract][Full Text] [Related]
13. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L; Cornett BL; Mackie K; Hohmann AG
Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
[TBL] [Abstract][Full Text] [Related]
14. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.
Slivicki RA; Xu Z; Kulkarni PM; Pertwee RG; Mackie K; Thakur GA; Hohmann AG
Biol Psychiatry; 2018 Nov; 84(10):722-733. PubMed ID: 28823711
[TBL] [Abstract][Full Text] [Related]
15. A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse.
Lin X; Xu Z; Carey L; Romero J; Makriyannis A; Hillard CJ; Ruggiero E; Dockum M; Houk G; Mackie K; Albrecht PJ; Rice FL; Hohmann AG
Pain; 2022 May; 163(5):834-851. PubMed ID: 35001054
[TBL] [Abstract][Full Text] [Related]
16. Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain.
Yuill MB; Hale DE; Guindon J; Morgan DJ
Mol Pain; 2017; 13():1744806917728227. PubMed ID: 28879802
[TBL] [Abstract][Full Text] [Related]
17. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Slivicki RA; Xu Z; Mali SS; Hohmann AG
Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid CB
Li AL; Carey LM; Mackie K; Hohmann AG
J Pharmacol Exp Ther; 2017 Aug; 362(2):296-305. PubMed ID: 28592614
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
Wilkerson JL; Ghosh S; Mustafa M; Abdullah RA; Niphakis MJ; Cabrera R; Maldonado RL; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Mar; 114():156-167. PubMed ID: 27890602
[TBL] [Abstract][Full Text] [Related]
20. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
Wilkerson JL; Niphakis MJ; Grim TW; Mustafa MA; Abdullah RA; Poklis JL; Dewey WL; Akbarali H; Banks ML; Wise LE; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2016 Apr; 357(1):145-56. PubMed ID: 26791602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
